Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01467882 · ClinicalTrials.gov registry record · Phase 3
Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty
A Phase 3 study, sponsored by Debiopharm International.
- Completed
- Registry status
- Phase 3
- Development phase
- 44
- Enrollment target
NCT01467882 is a Phase 3 study that has completed, run by Debiopharm International. The registered enrollment target is 44 participants.
The verdict
NCT01467882, a Phase 3 study, has completed, sponsored by Debiopharm International.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 44 participants
- Enrollment target
Study Summary
The study will investigate the efficacy, safety and pharmacokinetics of triptorelin 22.5 mg 6-month formulation in 44 patients suffering from central precocious puberty. The total study duration per patient will be 12 months (48 weeks).
Interventions
- DRUG Triptorelin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2012-04 |
| Est. Completion | 2014-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01467882
The ClinicalTrials.gov registry entry for NCT01467882 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Debiopharm International, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Triptorelin is the first listed.
NCT01467882 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01467882 about?
NCT01467882 is a clinical study titled "Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty". The study will investigate the efficacy, safety and pharmacokinetics of triptorelin 22.5 mg 6-month formulation in 44 patients suffering from central precocious puberty. The total study duration per patient will be 12 months (48 weeks).
What is the current status of trial NCT01467882?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 44 participants. The study started on 2012-04. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01467882?
The interventions under investigation include: Triptorelin (DRUG).
Who is sponsoring clinical trial NCT01467882?
This trial is sponsored by Debiopharm International, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.